Fulton Bank N.A. lowered its position in Bristol-Myers Squibb Company (NYSE:BMY) by 2.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,941 shares of the biopharmaceutical company’s stock after selling 572 shares during the quarter. Fulton Bank N.A.’s holdings in Bristol-Myers Squibb were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BMY. Ameriprise Financial Inc. raised its stake in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the last quarter. Swiss National Bank raised its stake in shares of Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares during the last quarter. State Street Corp raised its stake in shares of Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. Karp Capital Management Corp purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth approximately $38,890,000. Finally, Canada Pension Plan Investment Board raised its stake in shares of Bristol-Myers Squibb by 23.8% during the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock worth $182,859,000 after purchasing an additional 646,000 shares during the last quarter. Institutional investors own 68.88% of the company’s stock.

BMY has been the subject of several analyst reports. Jefferies Group LLC restated a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target for the company. in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 10th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $62.20.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/fulton-bank-n-a-trims-holdings-in-bristol-myers-squibb-company-bmy/1583155.html.

Bristol-Myers Squibb Company (BMY) traded up 0.05% during mid-day trading on Friday, hitting $63.36. The company had a trading volume of 3,667,703 shares. The company has a market cap of $103.91 billion, a PE ratio of 23.14 and a beta of 1.18. The company’s 50 day moving average price is $58.94 and its 200-day moving average price is $56.02. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.55.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.69 EPS. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.46%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.